Abstract: Described herein are compounds of Formula I and Formula II, methods of their synthesis, compositions comprising the compounds, and use of the compounds and compositions in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.

Abstract: Described herein are compounds of Formula I and Formula II, methods of their synthesis, compositions comprising the compounds, and use of the compounds and compositions in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.

Abstract: Described herein are compounds and chemical entities of Formula I, methods of their synthesis, compositions comprising them, and their use in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.

Abstract: The invention provides a chemical entity of Formula (I): (I), wherein R1, R2, R3, and R4, have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.

Abstract: Chemical entities of Formula (I): Including enantiomers thereof, wherein R1 has any of the values described herein, and compositions comprising such chemical entities; their preparation; and their use in various methods, including the treatment of depression, pain, cognitive disorders, neurodegenerative disorders, and other neurological and peripheral disorders.

Abstract: Implementations of the present disclosure include methods, systems, and computer-readable storage mediums for providing secure mobile data sharing. Actions can include: receiving, by the one or more processors, a request for secure mobile data sharing, the request being received from a mobile device and comprising a security definition; obtaining, by the one or more processors, based at least in part on the security definition of the request: a decryption key, a recipient identifier, and a security policy; receiving, by the one or more processors, a decryption request from a third-party device, the decryption request comprising an identifier distinguishing the third-party device as a recipient of an encrypted message corresponding to the decryption key; and providing the decryption key to the third-party device in response to validating the decryption request.

Abstract: Embodiments are configured for automating security design in IoT systems. The achievable security level for any given IoT system may be assessed based on the capabilities of each of the entities involved in its data path to generate a set of security policies for the IoT system. The capabilities of each entity involved in the IoT data path can be evaluated together with the capabilities of the communication links between entities. Based on these capabilities and user security preferences, the security policies can be generated to achieve a target level security. Based on this approach, security designs of IoT architectures can be developed through automated information collection.

Abstract: The invention provides a chemical entity of Formula (I): wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.

Abstract: Chemical entities of Formula (I): Including enantiomers thereof, wherein R1 has any of the values described herein, and compositions comprising such chemical entities; their preparation; and their use in various methods, including the treatment of depression, pain, cognitive disorders, neurodegenerative disorders, and other neurological and peripheral disorders.

Abstract: Described herein are compounds of Formula I and Formula II, methods of their synthesis, compositions comprising the compounds, and use of the compounds and compositions in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.

Abstract: The invention provides a chemical entity of Formula (I) wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.

Abstract: Chemical entities of Formula (I): Including enantiomers thereof, wherein R1 has any of the values described herein, and compositions comprising such chemical entities; their preparation; and their use in various methods, including the treatment of depression, pain, cognitive disorders, neurodegenerative disorders, and other neurological and peripheral disorders.

Abstract: Implementations of the present disclosure include methods, systems, and computer-readable storage mediums for receiving goal data and start-up information, the goal data indicating a goal to be achieved during a penetration test, the start-up information indicating initial data for beginning the penetration test, receiving tool data from a register of tools, the tool data including one or more tools that can be used during the penetration test, and, for each tool, input data required to execute the tool and output data provided by the tool, processing the goal data, the start-up information and the tool data to automatically generate attack tree data, the attack tree data including a plurality of data sets and links between data sets, and providing the attack tree data to display a graphical representation of an attack tree on a display.

Abstract: Embodiments are configured for automating security design in IoT systems. The achievable security level for any given IoT system may be assessed based on the capabilities of each of the entities involved in its data path to generate a set of security policies for the IoT system. The capabilities of each entity involved in the IoT data path can be evaluated together with the capabilities of the communication links between entities. Based on these capabilities and user security preferences, the security policies can be generated to achieve a target level security. Based on this approach, security designs of IoT architectures can be developed through automated information collection.

Abstract: Described herein are compounds and chemical entities of Formula I, methods of their synthesis, compositions comprising them, and their use in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.

Abstract: Described herein are compounds of Formula I and Formula II, methods of their synthesis, compositions comprising the compounds, and use of the compounds and compositions in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.

Abstract: The invention provides a chemical entity of Formula (I) wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.

Abstract: Implementations of the present disclosure include methods, systems, and computer-readable storage mediums for receiving goal data and start-up information, the goal data indicating a goal to be achieved during a penetration test, the start-up information indicating initial data for beginning the penetration test, receiving tool data from a register of tools, the tool data including one or more tools that can be used during the penetration test, and, for each tool, input data required to execute the tool and output data provided by the tool, processing the goal data, the start-up information and the tool data to automatically generate attack tree data, the attack tree data including a plurality of data sets and links between data sets, and providing the attack tree data to display a graphical representation of an attack tree on a display.

Abstract: Described herein are compounds of Formula I and Formula II, methods of their synthesis, compositions comprising the compounds, and use of the compounds and compositions in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.

Abstract: Described herein are compounds and chemical entities of Formula (I), methods of their synthesis, compositions comprising them, and their use in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.